PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Chronic administration of 16,17-dihydro-17b-hydroxy isomitraphylline (100mg/kg) in streptozotocin-treated rats markedly reduced plasma glucose concentration and increased glucose tolerance [PMID:22820565]
Methanolic leaf extract demonstrated dose-dependent inhibition of worm motility and MTT reduction, suggesting macrofilaricidal potential [PMID:39145368]
Leaf extract, mitraphylline, and green-synthesized silver nanoparticles (Mp-AgNPs) were evaluated for therapeutic potential in treating filariasis-induced secondary lymphedema [PMID:40901418]
Green-synthesized silver nanoparticles from M. parvifolia bark exhibited superior anti-inflammatory activity compared to crude plant extract [PMID:40680560]
Methanolic leaf extract exhibited significant antibacterial activity against Staphylococcus epidermidis, Bacillus cereus, and Salmonella typhi [PMID:39145368]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 39145368 (2024) — Mitragyna parvifolia as apotential therapeutic agent for lymphatic filariasis. · Journal of parasitic diseases : official organ of the Indian Society for Parasitology
- 2.PMID: 40901418 (2025) — Phytotherapeutic efficacy of Mitragyna parvifolia for acute dermatolymphangioadenitis (ADLA). · Journal of parasitic diseases : official organ of the Indian Society for Parasitology
- 3.PMID: 16872649 (2006) — Heteroyohimbinoid type oxindole alkaloids from Mitragyna parvifolia. · Phytochemistry
- 4.PMID: 40825067 (2025) — A chromosome-level Mitragyna parvifolia genome unveils spirooxindole alkaloid diversification and mitraphylline biosynthesis. · The Plant cell
- 5.PMID: 32837138 (2020)